Refine by
Potential Ad Therapeutic Equipment & Supplies
132 equipment items found
by:Aphios Corporation based inWoburn, MASSACHUSETTS (USA)
An alpha (α)-secretase modulator for ameliorating Alzheimer’s Disease pathophysiology and cognitive impairment with neuroprotection. Aphios is developing APH-1104, a more potent analog of Bryostatin-1, which is neuroprotective by α-secretase activation via novel PKC isoforms, down-regulation of pro-inflammatory and angiogenic processes and the substitution of β-amyloid for ...
Manufactured by:Feldan Therapeutics based inQuebec, QUEBEC (CANADA)
We have designed the Feldan Shuttle, a versatile biotechnology that enables safe and efficient delivery of therapeutic compounds into cells. By giving access to intracellular space, this unique technology is unlocking the potential of therapeutics that target intracellular components and contributes to the development of revolutionary ...
by:Orion Biotechnology Canada, Ltd. based inOttawa, SWITZERLAND
Orion’s platform and science unlocks the therapeutic potential of GPCR targets across a broad range of medical needs. Our approach allows us to focus our discovery and development efforts across peptide and protein GPCR subfamilies, generating a diversified pipeline of potential first-in-class/best-in-class antagonist and agonist therapies against high-value GPCR targets in ...
Manufactured by:Regeneron Pharmaceuticals Inc. based inTarrytown, NEW YORK (USA)
VelocImmune is our unique technology for producing fully human monoclonal antibodies. VelocImmune creates a multitude of optimized antibody drug candidates efficiently and directly from immunized mice. This approach overcomes the limitations of traditional platforms by rapidly creating fully human antibodies that tightly bind to therapeutic targets and avoid potential immune responses that may ...
by:Vir Biotechnology, Inc. based inSan Francisco, CALIFORNIA (USA)
We have established a robust method for capitalizing on unusually successful immune responses naturally occurring in people who are protected from, or have recovered from, infectious diseases. We identify rare antibodies from survivors that have the potential to treat and prevent rapidly evolving and/or previously untreatable pathogens via direct pathogen neutralization and immune system ...
Manufactured by:Boston Pharmaceuticals based inCambridge, MASSACHUSETTS (USA)
BOS-704 is a ghrelin O-acyl transferase inhibitor with therapeutic potential for multiple ...
Manufactured by:Altucell, Inc. based inNew York, NEW YORK (USA)
Encapsulated cell therapy is an emerging area of biopharmaceutical research that aims to unleash the therapeutic potential of cells to treat serious diseases without the need for immunosuppression. Altucell has developed patented, proprietary engineered cells that are combined with a patented encapsulation technology to create effective ...
Manufactured by:Boston Pharmaceuticals based inCambridge, MASSACHUSETTS (USA)
BOS-857 is a first-in-class, inhaled, small molecule furin inhibitor with therapeutic potential in pulmonary diseases, including cystic fibrosis (CF), vascular diseases, and infectious ...
Manufactured by:Celularity Inc. based inFlorham Park, NEW JERSEY (USA)
Celularity’s unique technology realizes the full promise of cell therapies by harnessing the immunomodulatory and regenerative properties of the postpartum ...
Manufactured by:SpliceBio based inBarcelona, SPAIN
SpliceBio specializes in addressing the challenges of gene therapy by leveraging engineered split inteins. Traditional adeno-associated virus (AAV) vectors are limited by size, restricting their ability to package only small genes, thus leaving many monogenic diseases without effective treatment solutions. The company has focused on the innovative application of inteins, a class of proteins that ...
by:Neoclease based inBoston, MASSACHUSETTS (USA)
Neoclease is pioneering the future of precision medicine through advanced technology in synthetic biology and generative AI. By developing synthetic nucleases, the company enhances gene editing processes to achieve unprecedented specificity and efficacy. These enzymes are meticulously crafted using proprietary algorithms powered by state-of-the-art GPT neural networks, which are capable of ...
Manufactured by:UroGen Pharma, Inc. based inPrinceton, NEW YORK (USA)
UroGen is evaluating UGN-301, our in-licensed anti-CTLA-4 antibody (zalifrelimab), as a monotherapy and as combination therapy with ...
Manufactured by:Impel Pharmaceuticals Inc. based inSeattle, WASHINGTON (USA)
Impel Pharmaceuticals has developed a proprietary drug delivery technology system that targets the vascular-rich upper nasal space,1 with multiple clinical trials suggesting rapid absorption and consistent drug bioavailability with ease of use in mind for a patient, provider or caregiver. Impel Pharmaceuticals proprietary Precision Olfactory Delivery (POD®) technology has the potential to ...
Manufactured by:Bayer AG based inLeverkusen, GERMANY
Small molecules (SMOLs) have long been in the focus of modern medicine. Over the last century, their advent revolutionized healthcare and improved the lives of patients all over the world. Most of today´s SMOLs exert their function by binding to proteins, thereby modulating their ability to catalyze biochemical reactions. However, a lot of proteins are difficult targets for SMOLs, since ...
Manufactured by:Inversago Pharma based inMontreal, QUEBEC (CANADA)
Inversago Pharma Inc. is focused on the development of peripherally-acting CB1 receptor (CB1) inverse agonists for the treatment of diabetic nephropathy, NASH, type 1 diabetes and Prader-Willi Syndrome. While previous generation of centrally-acting CB1 inhibitors presented safety concerns, the therapeutic relevance of peripheral CB1 pathway is still strongly supported by comprehensive scientific ...
Manufactured by:Regeneron Pharmaceuticals Inc. based inTarrytown, NEW YORK (USA)
VelociMab is a group of technologies that allow us to move with unprecedented speed from identification of a therapeutic antibody into clinical studies. VelociMab enables the high-throughput screening of potential therapeutic antibodies and the rapid generation of cell lines for recombinant human antibodies. It allows researchers to go from mouse immunization to production cell line bioreactor ...
by:Verb Biotics based inBoston, MASSACHUSETTS (USA)
Yso5 is a discovery-stage program leveraging a specific keystone gut bacteria (undisclosed) to potentiate the effects of Immune Checkpoint Blockade (ICB) drugs. The field of cancer therapy has been revolutionized by the use of immunotherapy. The microbiome breakthrough science today paves the way for innovative biotherapies to potentiate the effectiveness of these cancer immunotherapies. YSOPIA ...
Manufactured by:ExeVir Bio BV based inGhent, BELGIUM
XVR011, our lead compound is a potent, broadly neutralising SARS-COV-2 antiviral treatment. XVR011, an enhanced version of VHH72-FC, binds to a highly conserved region on the spikes of SARS-CoV-2, which are essential for the virus to enter the cell. It offers breadth and potency against a range of Sabecoviruses and is not impacted in its binding affinity to, or neutralising capacity of ...
Manufactured by:Ampersand Biosciences based inLake Clear, NEW YORK (USA)
Angiopoietin-related protein 7 (ANGPTL7), UniProt # O43827, is a 40kDa protein initially discovered in the cornea stromal layer. Increased levels have been observed in glaucoma and ANGPTL7 has been associated with various cancers including hepatic cancer metastasis. Studies have shown plasma levels are increased in obesity making it a potential therapeutic ...
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
Accessing a new repertoire of targets. Two classes of molecule with therapeutic potential that are not currently addressed by antibody drugs are G-protein-coupled receptors and ion channels, largely because they display small epitopes not accessible to traditional antibodies and their sequence is often conserved and thus less likely to be ...